Related Experiment Video
Updated: Jan 26, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
Safety biomarker applications in drug development
Shelli Schomaker1, Shashi Ramaiah1, Nasir Khan1
1Drug Safety R&D, Pfizer, Inc, CT, USA.
Abstract:
Biomarkers are invaluable drug development tools to assess and monitor safety in early clinical trials especially when exposure margins are limiting for promising therapeutics. Although progress has been made towards identifying and implementing translational safety biomarkers for a number of organ toxicities such as kidney and liver, significant biomarker gaps still exist to monitor toxicities for testis, pancreas, etc. Several precompetitive consortia [e.g., Predictive Safety Testing Consortia (PSTC), Innovative Medicines Initiative (IMI)] are working with industry, academia, government, patient advocacy groups and foundations with a goal to qualify biomarkers such that they can be used in preclinical studies and clinical trials to accelerate drug development. This manuscript discusses the complexities of novel biomarker discovery, validation and international regulatory qualifications intended for clinical trial applications and shares specific examples from Pfizer Research and Development. As safety biomarkers become widely accepted and qualified by the regulatory agencies, they will increasingly be implemented in early clinical trials, play a key role in decision making and facilitate the progression of promising therapeutics from preclinical through clinical development.
Insights
Safety biomarkers are crucial for early drug development, aiding in monitoring organ toxicities like kidney and liver. Despite progress, gaps remain for other organs, necessitating further research and qualification for broader clinical trial application.
Area of Science:
- Pharmacology
- Toxicology
- Biomarker Discovery
Background:
- Translational safety biomarkers are essential for assessing drug safety in early clinical trials, particularly when therapeutic exposure margins are narrow.
- While progress has been made in identifying biomarkers for kidney and liver toxicities, significant gaps persist for other organs such as the testis and pancreas.
- Precompetitive consortia, including the Predictive Safety Testing Consortia (PSTC) and Innovative Medicines Initiative (IMI), are actively working to qualify biomarkers for broader use.
Purpose of the Study:
- To discuss the complexities involved in the discovery, validation, and international regulatory qualification of novel safety biomarkers for clinical trial applications.
- To highlight specific examples and insights from Pfizer Research and Development regarding safety biomarker implementation.
- To emphasize the role of qualified safety biomarkers in accelerating drug development and facilitating therapeutic progression.
Main Methods:
- Review of current landscape and challenges in safety biomarker development.
- Discussion of precompetitive consortia efforts (PSTC, IMI) in biomarker qualification.
- Presentation of case examples from pharmaceutical industry research (Pfizer R&D).
Main Results:
- Progress in identifying and implementing safety biomarkers for certain organ toxicities (kidney, liver).
- Identification of existing biomarker gaps for other critical organs (testis, pancreas).
- Emphasis on the collaborative efforts of industry, academia, and regulatory bodies in biomarker qualification.
Conclusions:
- Qualified safety biomarkers are increasingly vital for early clinical trials, enhancing decision-making processes.
- The acceptance and qualification of safety biomarkers by regulatory agencies will accelerate the progression of promising therapeutics.
- Addressing biomarker gaps and fostering collaborative efforts are key to advancing drug safety assessment.
More Related Videos
14:22Free Radicals in Chemical Biology: from Chemical Behavior to Biomarker Development
Published on: April 15, 2013
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Related Concept Videos
Survey Safety
Household Wiring And Electrical Safety
In Vitro Drug Release Testing: Overview, Development and Validation
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Sustainable Development
Pharmacokinetics: Drug–Drug Interactions